Introduction Poor or inconsistent adherence to daily oral pre-exposure prophylaxis (PrEP)
has emerged as a key barrier to effective HIV prevention. The advent of potent long-acting …

Preexposure prophylaxis (PrEP) with antiretroviral medication has been proven effective in
reducing the risk for acquiring human immunodeficiency virus (HIV). The fixed-dose …

Pre-exposure prophylaxis (PrEP) with tenofovir (TFV) disoproxil fumarate and emtricitabine
administered orally daily is effective in preventing human immunodeficiency virus (HIV) …

Background. Daily, oral use of tenofovir disoproxil fumarate and emtricitabine (TDF-FTC) for
preexposure prophylaxis (PrEP) is an effective strategy to prevent acquisition of human …

Recent research has demonstrated how antiretrovirals (ARVs) could be effective in the
prevention of sexually transmitted HIV. We review research on the acceptability of oral pre …

As with other chronic conditions, adherence to daily medications remains a challenge for
many individuals living with HIV due to structural, behavioral, and social barriers …

Introduction: The efficacy of pre‐exposure prophylaxis (PrEP) in preventing sexual
acquisition of human immunodeficiency virus (HIV) is well established. Little is known about …

Introduction Randomized clinical trials have demonstrated the efficacy of antiretroviral pre‐
exposure prophylaxis (Pr EP) in preventing HIV acquisition among men who have sex with …

Nearly 2.3 million individuals worldwide are coinfected with human immunodeficiency virus
(HIV) and hepatitis C virus (HCV). Odds of HCV infection are six times higher in people living …

In 2012, the US FDA approved the first drug for use as HIV Pre-Exposure Prophylaxis
(PrEP), which is nearly 99% effective when taken as prescribed. Although the manifest …